ストックスクリーナーアプリを入手
0.527
2.75%
0.0141
プレマーケット:
.50
-0.027
-5.12%
Galmed Pharmaceuticals Ltd (GLMD) 最新ニュース
Galmed advances Parkinson’s drug formulation with higher CNS exposure - Investing.com
Galmed Pharmaceuticals Ltd - TradingKey
Galmed Pharmaceuticals Ltd (GLMD) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Galmed Pharmaceuticals Ltd. Revenue Breakdown – NASDAQ:GLMD - TradingView
GLMD|Galmed Pharmaceuticals Ltd|Price:0.513|Chg%:-0.040 - TradingKey
Galmed Pharmaceuticals Sets August 26, 2026 Annual Meeting to Approve Governance and Structural Changes - The Globe and Mail
GLMD Q2'26 Earnings: EPS estimate is (0.39) USD - TradingView
Galmed Pharmaceuticals (GLMD) sets 2026 AGM on name change and pay - Stock Titan
Galmed unveils heart-targeted Aramchol in cardiac fibrosis push - Indian Pharma Post
Galmed Accelerates Heart Failure Innovation with Aramchol - t.co
Galmed develops heart-targeted formulation of Aramchol drug By Investing.com - Investing.com South Africa
Galmed Develops Cardiac-Targeted Aramchol Formulation to Expand Cardiovascular Pipeline (NASDAQ:GLMD) - Yahoo Finance
Galmed develops heart-targeted formulation of Aramchol drug - Investing.com
Galmed Pharmaceuticals Ltd. (NASDAQ: GLMD) tests heart-targeted Aramchol LNPs - Stock Titan
Galmed Announces the Breakthrough Development of Novel LNP Cardiac Targeted Formulation of its SCD1 inhibitor, Aramchol - PR Newswire
Galmed Pharmaceuticals (GLMD) Sheds 4.75% as Biotech Volatility Pressures Near SupportPrice Action Signals - dars.gov.et
Galmed Pharmaceuticals (GLMD) Holds Steady at $0.57: Consolidation Phase with Key Levels in FocusSkew Index - dars.gov.et
Galmed Pharmaceuticals Reports Wider Q1 2026 Loss Amid Higher R&D Spending - TipRanks
Galmed (NASDAQ: GLMD) posts Q1 loss and closes Colospan acquisition - Stock Titan
Galmed Pharmaceuticals to Acquire Colospan to Create a GI-Focused Platform Targeting a $6 Billion Market - AOL.com
Galmed Pharmaceuticals (GLMD) Plunges Nearly 12% as Stock Tests Key Support at $0.54Trading Ideas - dars.gov.et
Galmed Pharmaceuticals (GLMD) Slides 12% as Selling Pressure Intensifies Near Key SupportMarket Neutral Pair - dars.gov.et
Galmed Pharmaceuticals Ltd. (GLMD) Q4 2025 Earnings: EPS Miss Extends Losses as Pre‑Revenue Biotech Faces Pipeline UncertaintyTrough Earnings Signal - DonanımHaber
GLMD Forecast — Price Target — Prediction for 2027 - TradingView
GLMD Should I Buy - Intellectia AI
Galmed Pharmaceuticals Ltd. Actuals & Estimates (NASDAQ:GLMD) - TradingView
GPH Forecast — Price Target — Prediction for 2027 - TradingView
Enterprise value to EBITDA forward of Galmed Pharmaceuticals Ltd. – NASDAQ:GLMD - TradingView
Price to book forward of Galmed Pharmaceuticals Ltd. – NASDAQ:GLMD - TradingView
Enterprise value to revenue forward of Galmed Pharmaceuticals Ltd. – NASDAQ:GLMD - TradingView
Price to sales forward of Galmed Pharmaceuticals Ltd. – NASDAQ:GLMD - TradingView
Enterprise value to EBIT forward of Galmed Pharmaceuticals Ltd. – NASDAQ:GLMD - TradingView
Galmed Pharmaceuticals Closes Amended All-Cash Colospan Acquisition With Earnout Structure - The Globe and Mail
Galmed completes acquisition of medical device firm Colospan - Investing.com UK
Galmed Pharmaceuticals finishes restructured Colospan deal - grafa.com
Form 6K Galmed Pharmaceuticals Ltd For: 22 June By Investing.com - Investing.com Nigeria
Galmed Pharmaceuticals Ltd. Announces Restructured Acquisition Terms For Colospan Ltd. - TradingView
Galmed completes acquisition of medical device firm Colospan By Investing.com - Investing.com Nigeria
Galmed (NASDAQ: GLMD) closes Colospan acquisition; $3.3M cash, up to $2M earnout - Stock Titan
Galmed (NASDAQ: GLMD) completes Colospan acquisition with cash and earnout - Stock Titan
Galmed buys CG-100 maker Colospan, eyes faster EU sales - Stock Titan
Galmed Pharmaceuticals (GLMD) Slips 3.37% as Shares Test Support Near $0.55Modified Schiff - DonanımHaber
Galmed Pharmaceuticals Ltd (GLMD) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Galmed Pharmaceuticals Ltd (GLMD) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Galmed Pharmaceuticals Declines 3.37% as Shares Approach Key Support at $0.55AAII Bearish - dars.gov.et
Galmed Pharmaceuticals Ltd (GLMD) Institutional Confidence - TradingKey
Galmed Pharmaceuticals Ltd (GLMD) Valuation: PE, PB & Fair Value Analysis - TradingKey
Galmed Pharmaceuticals Ltd (GLMD) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Galmed Pharmaceuticals Ltd (GLMD) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Galmed Pharmaceuticals Ltd (GLMD) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Galmed Pharmaceuticals (GLMD) Slips 7.31% as Stock Tests Key Support at $0.54New Highs New Lows - newsline.com
GLMD Q4 2025 Earnings: EPS Misses Estimates Amid Pre-Revenue PhaseEarnings Recovery Stocks - newsline.com
Maxim Group Maintains Galmed Pharmaceuticals(GLMD.US) With Hold Rating, Announces Target Price $0.55 - Moomoo
GLMD Q4 2025 Earnings: EPS Misses Estimates by Significant MarginEBITDA Analysis - newsline.com
Galmed to acquire Colospan for USD 4.5M - Medical Buyer
1.97%
0.83%
大文字化:
|
ボリューム (24 時間):